Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Longeveron LLC (LGVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: LGVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -92.79% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.70M USD | Price to earnings Ratio - | 1Y Target Price 8.88 |
Price to earnings Ratio - | 1Y Target Price 8.88 | ||
Volume (30-day avg) 381151 | Beta 0.35 | 52 Weeks Range 0.77 - 6.40 | Updated Date 03/30/2025 |
52 Weeks Range 0.77 - 6.40 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.62 |
Earnings Date
Report Date 2025-03-03 | When - | Estimate - | Actual -0.2741 |
Profitability
Profit Margin - | Operating Margin (TTM) -601.42% |
Management Effectiveness
Return on Assets (TTM) -53.14% | Return on Equity (TTM) -111.1% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4606854 | Price to Sales(TTM) 9.36 |
Enterprise Value 4606854 | Price to Sales(TTM) 9.36 | ||
Enterprise Value to Revenue 1.93 | Enterprise Value to EBITDA -49.61 | Shares Outstanding 13352800 | Shares Floating 11678916 |
Shares Outstanding 13352800 | Shares Floating 11678916 | ||
Percent Insiders 10.31 | Percent Institutions 8.72 |
Analyst Ratings
Rating 4 | Target Price 8.88 | Buy 3 | Strong Buy - |
Buy 3 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Longeveron LLC
Company Overview
History and Background
Longeveron Inc. was founded in 2014 and went public in 2021. It is a clinical stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Initial focus was on cell therapies derived from human Mesenchymal Stem Cells (MSCs).
Core Business Areas
- Cellular Therapies: Develops and commercializes Longeveron Human Mesenchymal Stem Cells (LMSC) based therapies. Primary focus on aging-related and specific life-threatening diseases.
Leadership and Structure
Dr. Josh Hare is the CEO and Co-Founder. Organizational structure includes research and development, clinical operations, regulatory affairs, and commercialization divisions.
Top Products and Market Share
Key Offerings
- LMSC (Longeveron Mesenchymal Stem Cells): Longeveron's lead product candidate, an allogeneic cellular therapy for aging-related frailty, Alzheimeru2019s disease, Metabolic Syndrome and hypoplastic left heart syndrome (HLHS). Currently in clinical trials. Market share is not applicable as the product is not yet commercially available. Competitors include other companies developing cell-based therapies, such as Mesoblast (MESO), Athersys (ATHX), and Lineage Cell Therapeutics (LCTX).
Market Dynamics
Industry Overview
The regenerative medicine industry is growing, driven by advancements in cell therapies and increasing demand for treatments for aging-related diseases. Regulatory pathways are evolving, and the market remains competitive.
Positioning
Longeveron is a clinical-stage biotechnology company focused on aging-related diseases. Its competitive advantage lies in its proprietary LMSC technology and clinical trial data.
Total Addressable Market (TAM)
The total addressable market for aging-related diseases and regenerative medicine is significant, estimated in the billions of dollars. Longeveron is positioned to capture a portion of this market pending successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary LMSC technology platform
- Experienced management team
- Advancing clinical trials
- Strong intellectual property portfolio
Weaknesses
- Clinical stage company with no currently approved products
- Limited financial resources
- Dependence on clinical trial success
- Reliance on strategic partnerships
Opportunities
- Positive clinical trial outcomes
- Regulatory approval of LMSC
- Expansion of LMSC applications to other diseases
- Strategic partnerships and collaborations
- Increased awareness of regenerative medicine
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other cell therapy companies
- Difficulty securing funding
- Changes in the regulatory landscape
Competitors and Market Share
Key Competitors
- MESO
- ATHX
- LCTX
Competitive Landscape
Longeveron competes with other cell therapy companies. Advantages include its proprietary LMSC technology. Disadvantages include its limited financial resources and clinical stage status.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on R&D and clinical trial progress.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approval, and commercialization of LMSC. Analyst estimates would provide projections for revenue, earnings, and market capitalization.
Recent Initiatives: Recent initiatives include advancing clinical trials for LMSC in various indications, securing funding, and establishing partnerships.
Summary
Longeveron is a clinical-stage biotechnology company with promising LMSC technology focused on aging-related conditions. Its success hinges on positive clinical trial outcomes and securing regulatory approval. Financial constraints and competition remain key challenges. Future partnerships would be critical for long-term growth.
Similar Companies
- MESO
- ATHX
- LCTX
- BMY
- PFE
Sources and Disclaimers
Data Sources:
- Longeveron Inc. Website
- SEC Filings
- Analyst Reports
- Company Presentations
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated and may not be precise. Investing in clinical-stage biotechnology companies is highly speculative and involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Longeveron LLC
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2021-02-12 | CEO & Director Mr. Mohamed Wa'el Ahmed Hashad M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://longeveron.com |
Full time employees 25 | Website https://longeveron.com | ||
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.